SG11201806393QA - Use of gabaa receptor modulators for treatment of itch - Google Patents

Use of gabaa receptor modulators for treatment of itch

Info

Publication number
SG11201806393QA
SG11201806393QA SG11201806393QA SG11201806393QA SG11201806393QA SG 11201806393Q A SG11201806393Q A SG 11201806393QA SG 11201806393Q A SG11201806393Q A SG 11201806393QA SG 11201806393Q A SG11201806393Q A SG 11201806393QA SG 11201806393Q A SG11201806393Q A SG 11201806393QA
Authority
SG
Singapore
Prior art keywords
international
itch
pct
general formula
treatment
Prior art date
Application number
SG11201806393QA
Inventor
Hanns Ulrich Zeilhofer
William Ralvenius
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of SG11201806393QA publication Critical patent/SG11201806393QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/129801 Al 3 August 2017 (03.08.2017) WIPO I PCT 111111111111110111011111111111010111110 III 011101111111111011111011111111111110111111 (51) International Patent Classification: A61K 31/437 (2006.01) A61K 31/5513 (2006.01) A61K 31/5025 (2006.01) A61K 31/5517 (2006.01) A61K 31/519 (2006.01) A61P 17/04 (2006.01) (21) International Application Number: PCT/EP2017/051866 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16153035.7 27 January 2016 (27.01.2016) EP 16178824.5 11 July 2016 (11.07.2016) EP (71) Applicant: UNIVERSITAT ZURICH [CH/CH]; Ramistr. 71, CH-8006 Zilrich (CH). (72) Inventors: ZEILHOFER, Hanns Ulrich; Adlisbergstrasse 88, 8044 Ziirich (CH). RALVENIUS, William; Milch- buckstrasse 9, 8057 Ziirich (CH). (74) Agent: BOLSINGER, Jens; Schulz Junghans Patentan- walte PartGmbB, GroBbeerenstraBe 71, 10963 Berlin (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) W O 20 17 / 12980 1 Al (54) Title: USE OF GABA RECEPTOR MODULATORS FOR TREATMENT OF ITCH A (57) : A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (la), general formula (lb) or general formula (lc). The compounds of the invention are positive allosteric ct2 and/or ct3 GABAA receptor modulators.
SG11201806393QA 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch SG11201806393QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16178824 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Publications (1)

Publication Number Publication Date
SG11201806393QA true SG11201806393QA (en) 2018-08-30

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806393QA SG11201806393QA (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Country Status (14)

Country Link
US (2) US10786513B2 (en)
EP (1) EP3407886A1 (en)
JP (2) JP7115746B2 (en)
KR (1) KR102482200B1 (en)
CN (1) CN108697694B (en)
AU (1) AU2017213154B2 (en)
BR (1) BR112018015386A2 (en)
CA (2) CA3012791C (en)
CL (1) CL2018002023A1 (en)
IL (1) IL260775B (en)
MX (1) MX2018009252A (en)
SG (1) SG11201806393QA (en)
UA (1) UA125463C2 (en)
WO (1) WO2017129801A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7115746B2 (en) 2016-01-27 2022-08-09 ウニヴェルズィテート・ツューリヒ Use of GABAA receptor modulators for the treatment of pruritus
EP3781566A4 (en) * 2018-04-18 2022-06-22 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
SG11202101360VA (en) 2018-09-13 2021-03-30 Saniona As A gabaa receptor ligand
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
CN110004118B (en) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 Packaging method and application of rAAV (rapid access Virus) for assisting recombinant rabies virus in efficient reverse cross-single-stage synapse of nerve cells
JP2022554159A (en) * 2019-10-23 2022-12-28 ニューロサイクル・セラピューティクス・インコーポレイテッド Treatment of epileptic conditions with GABAA receptor modulators
US20210401849A1 (en) * 2020-06-30 2021-12-30 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
BR9710729A (en) 1996-07-25 1999-08-17 Merck Sharp & Dohme Compound Pharmaceutical composition uses a compound and process for the treatment and / or prevention of anxiety and seizures for the screening of non-sedative anxiolytic compounds and for the preparation of a compound
FR2767692B1 (en) * 1997-09-01 2000-03-03 Oreal USE OF A AGONIST SUBSTANCE OF A RECEPTOR ASSOCIATED WITH A CHLORINE OR POTASSIAL CHANNEL IN THE TREATMENT OF SENSITIVE SKIN
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
DE60115282T2 (en) 2000-11-10 2006-08-10 Merck Sharp & Dohme Ltd., Hoddesdon IMIDAZOTRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
MXPA04009332A (en) 2002-03-28 2005-12-12 Wisys Technology Found Inc Anxiolytic agents with reduced sedative and ataxic effects.
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (en) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd Screening method for cutaneous disease therapeutic agent
JPWO2005030773A1 (en) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 New pyrazolopyrimidine derivatives
WO2005108401A1 (en) * 2004-04-29 2005-11-17 Dov Pharmaceutical, Inc. 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (en) * 2005-01-28 2006-08-02 주식회사 대웅제약 Novel benzoimidazole derivatives and a pharmaceutical composition comprising the same
DE602007011773D1 (en) 2006-08-04 2011-02-17 Merz Pharma Gmbh & Co Kgaa SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE
HUE026659T2 (en) 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
SI2300455T1 (en) 2008-05-21 2017-12-29 Incyte Holdings Corporation Salts of 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)- imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide and processes related to preparing the same
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
BRPI1014284A2 (en) 2009-04-22 2017-10-10 Janssen Pharmaceutica Nv azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2456311A4 (en) 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc Substituted imidazotriazines
JP5894161B2 (en) 2010-08-25 2016-03-23 ネオファーム カンパニー， リミテッド Novel heterocyclic compound and composition for treating inflammatory disease using the same
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
KR20150118148A (en) * 2013-02-19 2015-10-21 오노 야꾸힝 고교 가부시키가이샤 Trk-INHIBITING COMPOUND
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US10259815B2 (en) 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
JP7115746B2 (en) 2016-01-27 2022-08-09 ウニヴェルズィテート・ツューリヒ Use of GABAA receptor modulators for the treatment of pruritus

Also Published As

Publication number Publication date
CN108697694A (en) 2018-10-23
KR20180118623A (en) 2018-10-31
JP2019507736A (en) 2019-03-22
US20190134057A1 (en) 2019-05-09
JP2022088620A (en) 2022-06-14
EP3407886A1 (en) 2018-12-05
US20210100814A1 (en) 2021-04-08
CN108697694B (en) 2022-12-09
RU2018128905A (en) 2020-02-27
CL2018002023A1 (en) 2019-02-01
WO2017129801A1 (en) 2017-08-03
IL260775B (en) 2021-09-30
US10786513B2 (en) 2020-09-29
JP7115746B2 (en) 2022-08-09
CA3222584A1 (en) 2017-08-03
KR102482200B1 (en) 2022-12-27
US11529359B2 (en) 2022-12-20
AU2017213154A1 (en) 2018-08-16
BR112018015386A2 (en) 2019-03-19
CA3012791C (en) 2024-01-23
MX2018009252A (en) 2019-01-21
AU2017213154B2 (en) 2023-02-02
RU2018128905A3 (en) 2020-03-24
CA3012791A1 (en) 2017-08-03
UA125463C2 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201909011PA (en) Niraparib compositions
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201808108XA (en) Synthesis of indazoles
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201407200TA (en) Liquid formulation
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201805001UA (en) Method of treating influenza a
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804587QA (en) Isoindole compounds
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201408509PA (en) Racecadotril lipid compositions